Jerome B. Zeldis

CIK: 0001433982

Transaction Breakdown

Open Market Buys (P)1 (4.5%)

High conviction signal

Open Market Sales (S)5 (22.7%)

Position reduction

Option Exercises (M)2 (9.1%)

Derivative conversions

Awards (A)8 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)6 (27.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

SNGX

SOLIGENIX, INC.

Director

PTCT

PTC THERAPEUTICS, INC.

Director

NXGL

NEXGEL, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (22 total)

SNGX
SOLIGENIX, INC.
Oct 12, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
63 shares-
SNGX
SOLIGENIX, INC.
Oct 12, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
192 shares-
SNGX
SOLIGENIX, INC.
Oct 12, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
121 shares-
SNGX
SOLIGENIX, INC.
Oct 12, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
54 shares-
SNGX
SOLIGENIX, INC.
Oct 12, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
128 shares-
SNGX
SOLIGENIX, INC.
Oct 12, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
74 shares-
SNGX
SOLIGENIX, INC.
Sep 17, 2026
Award(A)
Stock Option (Right to Buy)
Direct
78.9K shares-
PTCT
PTC THERAPEUTICS, INC.
Jan 2, 2026
Award(A)
Direct
4K shares-
NXGL
NEXGEL, INC.
Jun 25, 2025
Award(A)
Stock Option (Right to Buy)
Direct
30K shares-
SNGX
SOLIGENIX, INC.
Jun 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
17.6K shares-
PTCT
PTC THERAPEUTICS, INC.
Jan 3, 2025
Award(A)
Direct
4K shares-
SNGX
SOLIGENIX, INC.
Dec 12, 2024
Award(A)
Stock Option (Right to Buy)
Direct
8.6K shares-
PTCT
PTC THERAPEUTICS, INC.
Dec 2, 2024
Sale(S)
Direct
3.7K shares at avg. $52.39$192K
PTCT
PTC THERAPEUTICS, INC.
Dec 2, 2024
Sale(S)
Direct
5.7K shares at avg. $50.52$288K
PTCT
PTC THERAPEUTICS, INC.
Dec 2, 2024
Exercise(M)
Direct
12K shares at avg. $30.86$370K
PTCT
PTC THERAPEUTICS, INC.
Dec 2, 2024
Sale(S)
Direct
3.2K shares at avg. $52.42$167K
PTCT
PTC THERAPEUTICS, INC.
Dec 2, 2024
Sale(S)
Direct
8.8K shares at avg. $51.44$453K
PTCT
PTC THERAPEUTICS, INC.
Dec 2, 2024
Exercise(M)
Direct
12K shares at avg. $51.00$612K
PTCT
PTC THERAPEUTICS, INC.
Dec 2, 2024
Sale(S)
Direct
2.6K shares at avg. $51.43$135K
NXGL
NEXGEL, INC.
Nov 20, 2024
Award(A)
Warrant to Purchase Common Stock
Direct
1.8K shares-
NXGL
NEXGEL, INC.
Nov 20, 2024
Purchase(P)
Direct
3.6K shares at avg. $2.75$10K
NXGL
NEXGEL, INC.
Sep 13, 2024
Award(A)
Stock Option (Right to Buy)
Direct
25K shares-

		Type	Shares	Price		Ownership
Oct 12, 2026	SNGX SOLIGENIX, INC.	Disposition(D) Stock Option (Right to Buy)	63	-	-	Direct
Oct 12, 2026	SNGX SOLIGENIX, INC.	Disposition(D) Stock Option (Right to Buy)	192	-	-	Direct
Oct 12, 2026	SNGX SOLIGENIX, INC.	Disposition(D) Stock Option (Right to Buy)	121	-	-	Direct
Oct 12, 2026	SNGX SOLIGENIX, INC.	Disposition(D) Stock Option (Right to Buy)	54	-	-	Direct
Oct 12, 2026	SNGX SOLIGENIX, INC.	Disposition(D) Stock Option (Right to Buy)	128	-	-	Direct
Oct 12, 2026	SNGX SOLIGENIX, INC.	Disposition(D) Stock Option (Right to Buy)	74	-	-	Direct
Sep 17, 2026	SNGX SOLIGENIX, INC.	Award(A) Stock Option (Right to Buy)	78,947	-	-	Direct
Jan 2, 2026	PTCT PTC THERAPEUTICS, INC.	Award(A)	4,000	-	$0	Direct
Jun 25, 2025	NXGL NEXGEL, INC.	Award(A) Stock Option (Right to Buy)	30,000	-	-	Direct
Jun 20, 2025	SNGX SOLIGENIX, INC.	Award(A) Stock Option (Right to Buy)	17,647	-	-	Direct
Jan 3, 2025	PTCT PTC THERAPEUTICS, INC.	Award(A)	4,000	-	$0	Direct
Dec 12, 2024	SNGX SOLIGENIX, INC.	Award(A) Stock Option (Right to Buy)	8,646	-	-	Direct
Dec 2, 2024	PTCT PTC THERAPEUTICS, INC.	Sale(S)	3,667	$52.39	$192,114	Direct
Dec 2, 2024	PTCT PTC THERAPEUTICS, INC.	Sale(S)	5,699	$50.52	$287,913	Direct
Dec 2, 2024	PTCT PTC THERAPEUTICS, INC.	Exercise(M)	12,000	$30.86	$370,320	Direct
Dec 2, 2024	PTCT PTC THERAPEUTICS, INC.	Sale(S)	3,187	$52.42	$167,063	Direct
Dec 2, 2024	PTCT PTC THERAPEUTICS, INC.	Sale(S)	8,813	$51.44	$453,341	Direct
Dec 2, 2024	PTCT PTC THERAPEUTICS, INC.	Exercise(M)	12,000	$51.00	$612,000	Direct
Dec 2, 2024	PTCT PTC THERAPEUTICS, INC.	Sale(S)	2,634	$51.43	$135,467	Direct
Nov 20, 2024	NXGL NEXGEL, INC.	Award(A) Warrant to Purchase Common Stock	1,818	-	-	Direct
Nov 20, 2024	NXGL NEXGEL, INC.	Purchase(P)	3,636	$2.75	$9,999	Direct
Sep 13, 2024	NXGL NEXGEL, INC.	Award(A) Stock Option (Right to Buy)	25,000	-	-	Direct

1-22 of 22 transactions

About ZELDIS JEROME B

ZELDIS JEROME B (SEC CIK 0001433982) files insider reports with the SEC as Director of SOLIGENIX, INC. (SNGX), Director of PTC THERAPEUTICS, INC. (PTCT) and Director of NEXGEL, INC. (NXGL).

Signal8 holds 10 ownership filings by ZELDIS JEROME B, all Form 4s, filed between Sep 17, 2024 and Oct 13, 2026. Those filings report 22 transactions, from Sep 13, 2024 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on ZELDIS JEROME B's filings is in PRINCETON, NJ.

Recent filings by ZELDIS JEROME B

Oct 12, 2026: Disposition to issuer transactions of SNGX derivative securities (6 lines, Form 4, code D).
Sep 17, 2026: Grant or award of SNGX derivative securities (Form 4, code A).
Jan 2, 2026: Grant or award of PTCT shares (Form 4, code A).
Jun 25, 2025: Grant or award of NXGL derivative securities (Form 4, code A).
Jun 20, 2025: Grant or award of SNGX derivative securities (Form 4, code A).

Other insiders filing for SOLIGENIX, INC. (SNGX)

RUBIN ROBERT J., Director
Parks Diane L., Director
LAPOINTE ANTHONY GREGG, Director
Donini Oreola, CSO
Guarino Jonathan L., CFO
SCHABER CHRISTOPHER J, CHAIRMAN, CEO AND PRESIDENT

How to read Form 4 transaction codes